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Abstract: In the last decade, the environment for medicines development has undergone unprecedented change, in-
cluding: a shift from predominantly big Pharma to one of extensive industry–academia and SME partnerships and col-
laborations, greater emphasis on understanding the molecular basis of disease for stratified and personalised medicine, 
and a focus on societal/patients’ needs and priorities. 
A variety of European initiatives have been established to support the training of scientists/professionals involved in 
medicines development in order to respond to this constantly changing, demanding, and chaotic landscape. Some of 
these initiatives are directed specifically at medicines development, some address scientific research including training 
relevant to medicines development, and some support general training needs which can include medicines development. 
There are a number of European initiatives supporting better training in medicines development. They differ in their 
approach, ranging from IMI (specific to medicines development) to Erasmus+ (boosting skills and employability in all 
areas). The scope, budgets, and requirements differ considerably and they each have to be reviewed in detail to decide 
which might be the most appropriate for a particular target group. The common theme is to support the aims of the Eu-
ropean Research Area (ERA), i.e., a significant improvement in Europe’s research performance to promote growth and 
job creation. 
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1. Introduction 
n the last decade, the environment for medicines 
development has undergone unprecedented change 
including: 
• a shift from predominantly big Pharma to one 
of extensive industry–academia and SME 
partnerships and collaborations; 
• greater emphasis on understanding the mole-
cular basis of disease for stratified and perso-
nalised medicine; 
• and a focus on societal/patients’ needs and 
priorities. 
A variety of European initiatives have been estab-
lished to support the training of scientists and profes-
sionals involved in medicines development in order to 
respond to this constantly changing, demanding and 
chaotic landscape. Some of these initiatives are di-
rected specifically at medicines development, some 
address scientific research including training relevant 
to medicines development, and some support general 
training needs which can include medicines develop-
ment. The major initiatives are described below. 
2. Innovative Medicines Initiative (IMI) Projects 
The biggest driver of training in medicines develop-
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ment is the Innovative Medicines Initiative (IMI)[1], 
“Europe’s largest public–private initiative aiming to 
speed up the development of better and safer medi-
cines for patients. IMI supports collaborative research 
projects and builds networks of industrial and aca-
demic experts in order to boost pharmaceutical inno-
vation in Europe. It is a joint undertaking between the 
European Union and the European Federation of 
Pharmaceutical Industries and Associations (EFPIA).” 
IMI1 covered the project applications from 2009– 
2014 and was part of EU Framework Project 7 (FP7); 
IMI2 covers the period from 2014–2020 and is part of 
Horizon 2020. 
In IMI1, education and training needs were defined 
in the Research Agenda[2] as the “fourth pillar” re-
quired to remove bottlenecks in the medicines devel-
opment process. Five projects were set up to address 
these gaps: 
• the European Medicines Research Training 
Network[3],  
• the European Programme in Pharmacovigil-
ance and Pharmacoepidemiology[4] , 
• the Pharmaceutical Medicine Training Pro-
gramme[5],  
• the European Modular Education and Train-
ing Programme in Safety Sciences for Medi-
cines[6],  
• and the European Patient Academy for The-
rapeutic Innovation (EUPATI)[7]. 
All are public–private partnerships (PPPs) designed to 
provide better training in aspects of medicines devel-
opment. EUPATI provides education for patients 
whilst the other projects address the needs of the 
scientific community. 
Three of the projects (Eu2P, PharmaTrain and Sa-
feSciMET) have developed flexible, Master’s-level 
modular programmes. The modules can be taken as 
short courses for continuing professional development 
(CPD) or combined to provide certificates, diplomas 
or, in combination with a dissertation, a Master’s de-
gree. These projects have addressed the challenges of 
collaboration between universities, and between uni-
versities and industry. Different models have evolved, 
including several universities each delivering the same 
curriculum to the same standards (e.g. PharmaTrain), 
several universities jointly delivering a single pro-
gramme and providing joint certificates or a joint 
Master’s degree (e.g. Eu2P), and several universities 
jointly delivering a single programme where one uni-
versity awards a Master’s degree (SafeSciMET). Both 
the content and the teaching methodologies (dis-
tance-learning, e-learning, e-lite, blended learning and 
face-to-face) have been developed to address the 
changing and diverse needs of their respective au-
diences. The consortia combine academic pedagogic 
expertise with practical industry experience—bridging 
education and professional training. PharmaTrain has 
also developed a library[8] of free e-learning pro-
grammes as an introduction to many of the course 
modules. 
EMTRAIN has developed tools, processes, and net-
works to support education and training. The course 
catalogue on-course®[9,10] contains around 7000 post-
graduate courses in biomedical sciences (Master’s, 
short courses and PhD programmes), incorporating 
quality standards[11] developed by the IMI Education 
and Training projects, a teaching methodologies tool-
kit, and flags from professional/scientific bodies indi-
cating which courses meet their requirements (Figure 1). 
This is also used for research into European courses 
and for gap analysis. The LifeTrain[12] framework for 
CPD in biomedical sciences focuses on competency 
profiles, competence assessments and competency 
portfolios, i.e., training beyond knowledge acquisi-
tion[13]. The third “product” is a cohort of indus-
try-aware, early-stage researchers supported with a 
framework document, annual workshops and a Linke-
dIn network. 
Recently EMTRAIN, Eu2P, PharmaTrain and Saf-
eSciMET successfully obtained additional IMI fund-
ing and work collaboratively as IMI-TRAIN. This 
allows the strengths of the different projects to be 
combined. For example, Eu2P which has a distance 
learning programme has worked with colleagues from 
SafeSciMET to convert some of their face-to-face pro-
grammes into blended learning programmes. Another 
example would be the PharmaTrain/IFAPP compe-
tency profile for specialists in medicines develop-
ment[14] moving into an implementation phase with a 
pilot study being undertaken in Italy. EMTRAIN/ 
PharmaTrain expertise in competency development is 
also being used by SafeSciMET to develop a new 
competency profile for drug safety scientists.  
EUPATI has developed a regional network to sup-
port the programme, an advanced training course in 
medicines development with a face-to-face course for 
100 patient advocates, and an extensive, multi-lan-
guage toolbox of training resources which is being 
rolled out to over 100,000 patients across Europe. In 
the context of EUPATI, a patient advocate is a repre- 
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Figure 1. Homepage of the on-course® website. 
 
sentative of a patient organisation who influences the 
health policy environment to ensure it reflects the 
views of the organisation and a genuine patient’s 
perspective. 
In addition, many of the IMI science projects have 
developed training materials based on their discove-
ries, either alone or in conjunction with one of the 
education and training projects. For example, the re-
sults about safety biomarker research from the project 
SAFE-T[15] are being integrated into the SafeSciMET 
courses. IMI2 has a Strategic Research Agenda which 
includes training as part of the Implementation Strat-
egy section. However, there have not yet been any 
training project proposals announced for IMI2. 
3. European Strategy Forum for Research In-
frastructures (ESFRI) in Biological and Med-
ical Sciences (BMS) and Research Infrastruc-
tures (RIs) 
The ESFRI BMS Research Infrastructures[16] were set 
up to contribute to the implementation of the Europe 
2020 strategy and its Innovation Union Flagship Initi-
ative, and enable the building up of the European Re-
search Area (ERA)[17]. They are at various stages in 
their development. Six such infrastructures are now 
established as legal entities and provide training both 
internally and externally:  
• The European Clinical Research Infrastruc-
ture Network (ECRIN-ERIC)[18], 
• Bio-banking and Bio-molecular Resources 
Infrastructure (BBMRI-ERIC)[19], 
• European Infrastructure for Translational 
Medicine (EATRIS-ERIC)[20], 
• European Life-sciences Infrastructure for Bio-
logical Information (ELIXIR/EMBL)[21], 
• European Research Infrastructure for pheno-
typing and archiving of model mammalian 
genomes (INFRAFRONTIER GmBH)[22], 
• Structural Biology Research Infrastructure 
(INSTRUCT)[23]. 
They are also partners in EMTRAIN. The other seven 
BMS RIs are in the preparatory phase, during which 
training is internal only. 
All of these RIs provide training in their respective 
area of expertise. These are all highly relevant to me-
dicines development. In most cases, the training is 
very practical, e.g. advanced RNA-Seq and CHIP-Seq 
analysis, hands-on experience of high throughput pro-
tein (HTP) expression screening with an emphasis on 
methods to study “difficult” targets, and mouse clinic 
state-of-the-art phenotyping technologies. In some 
cases, the courses are developed in conjunction with 
an industry advisory committee (e.g. ELIXIR). 
Within Horizon 2020 there is also funding for 
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“strengthening the human capital of research infra-
structures” e.g. INFRASUPP-3[24]. These are specific 
to the RIs but address the training needs of researchers 
working in these areas which have broader relevance. 
There have been opportunities for an RI to collabo-
rate directly with an IMI education and training 
project. For example, ECRIN and PharmaTrain have 
jointly developed a European approach to clinical in-
vestigator training[25] which includes an e-learning 
programme, e-CLIC. 
4. Marie Skłodowska–Curie Actions 
“The Marie Skłodowska–Curie Actions (MSCA)[26] 
provide grants for all stages of researchers’ ca-
reers—be they doctoral candidates or highly expe-
rienced researchers—and encourage transnational, 
intersectoral and interdisciplinary mobility. The 
MSCA enable research-focused organisations (univer-
sities, research centres, and companies) to host ta-
lented foreign researchers and to create strategic part-
nerships with leading institutions worldwide. The 
MSCA aim to equip researchers with the necessary 
skills and international experience for a successful 
career, either in the public or the private sector. The 
programme responds to the challenges sometimes 
faced by researchers, offering them attractive working 
conditions and the opportunity to move between aca-
demic and other settings.” 
These programmes now include: 
• Research networks (ITN): support for Innova-
tive Training Networks that organise research 
training programmes providing experience 
outside academia, hence developing innova-
tion and employability skills. ITNs include 
industrial doctorates, in which non-academic 
organisations have an equal role to universi-
ties with respect to the researcher’s time and 
supervision, and joint doctoral degrees deli-
vered by several universities. Furthermore, 
non-European organisations can participate as 
additional partners in ITNs, enabling doctor-
al-level candidates to gain experience outside 
Europe during their training. 
• Individual fellowships (IF) to support expe-
rienced researchers undertaking mobility be-
tween countries, optionally to the non-acade-
mic sector. 
• Research and Innovation Staff Exchanges 
(RISE), to provide international and inter-sec-
toral cooperation. RISE supports short-term 
mobility of research and innovation staff at all 
career levels, from the most junior (post- 
graduate) to the most senior (management). 
• Co-funding of regional, national and interna-
tional programmes (COFUND) that finance 
fellowships involving mobility to or from 
another country. 
5. The European & Developing Countries 
Clinical Trials Partnership (EDCTP) 
EDCTP[27] is funded by Horizon 2020[28]. “EDCTP 
aims to accelerate the development of new or im-
proved drugs, vaccines, microbicides and diagnostics 
against HIV/AIDS, tuberculosis and malaria as well as 
other poverty-related and neglected infectious diseases 
in Sub-Saharan Africa, with a focus on phase II and III 
clinical trials.” 
One of their activities is capacity building with 
training to support the clinical trials, e.g. a fellowship 
programme. The fellowship scheme targets junior- to 
mid-career researchers or clinical staff who are em-
ployed by an institution in a low- to middle-income 
country (LMIC) where they are working on activities 
within the scope of EDCTP. Fellows are expected to 
improve their professional skills significantly through 
the fellowships, and upon their return they will also 
contribute to enhanced capacity of research institu-
tions in LMICs, including training of peers. Further-
more, the scheme will strengthen collaboration be-
tween research institutions, researchers and clinical 
staff in LMICs, and pharmaceutical companies. 
6. European Institute of Innovation and Tech-
nology (EIT) and Knowledge Innovation 
Communities (KICs) 
“The EIT is an independent EU body set up in 2008 to 
spur innovation and entrepreneurship across Europe to 
overcome some of its greatest challenges. It brings to-
gether leading universities, research labs and compa-
nies to form dynamic cross-border partnerships— 
Knowledge and Innovation Communities, KICs—that 
develop innovative products and services, start new 
companies, and train a new generation of entrepre-
neurs.[29]”  
In 2015, a new KIC in Healthy Living and Active 
Ageing[30] was approved. The partnership will pro-
mote entrepreneurship and develop innovations for 
healthy living and active ageing, providing Europe 
with new opportunities and resources. This will be 
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achieved through delivering products, concepts and 
services, including educational programmes that will 
nurture talents and train the workforce of tomorrow. 
Their stated aim is: “by 2018, to create, among others, 
70 start-ups per year and have 1,000,000 students par-
ticipating in our educational online programmes per 
year.” This new generation of entrepreneurs are likely 
to work in the area of medicines development as well 
as many others. 
7. Erasmus+ 
Erasmus+[31] is the new EU programme for Education, 
Training, Youth and Sport for 2014–2020. The Eras-
mus+ programme aims to boost skills and employabi-
lity, as well as modernise Education, Training, and 
Youth work. The opportunities for education and 
training include: Strategic Partnerships in the field of 
education and training, Knowledge Alliances, and 
Sector Skills Alliances. These programmes support all 
fields of education and training. 
8. Conclusions 
There are a number of European initiatives supporting 
better training in medicines development. They differ 
in their approach, ranging from IMI (specific to medi-
cines development) to Erasmus+ (boosting skills and 
employability in all areas). The scopes, budgets, and 
requirements differ considerably and they each have 
to be reviewed in detail to decide which might be the 
most appropriate for a particular target group. The 
common theme is to support the aims of the ERA[17], 
i.e., a significant improvement in Europe’s research 
performance, to promote growth and job creation. 
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